AR041136A1 - Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas - Google Patents
Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinasInfo
- Publication number
- AR041136A1 AR041136A1 ARP030103191A ARP030103191A AR041136A1 AR 041136 A1 AR041136 A1 AR 041136A1 AR P030103191 A ARP030103191 A AR P030103191A AR P030103191 A ARP030103191 A AR P030103191A AR 041136 A1 AR041136 A1 AR 041136A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nr5r10
- cycloalkyl
- aryl
- group
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000003118 aryl group Chemical group 0.000 abstract 15
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 15
- 125000001072 heteroaryl group Chemical group 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 5
- 230000001154 acute effect Effects 0.000 abstract 3
- 208000032839 leukemia Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 206010025323 Lymphomas Diseases 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000001685 thyroid gland Anatomy 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 abstract 1
- 206010003571 Astrocytoma Diseases 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 108091007914 CDKs Proteins 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 abstract 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 201000008808 Fibrosarcoma Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 206010023347 Keratoacanthoma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025280 Lymphocytosis Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 201000010208 Seminoma Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- -1 alkylalkyl Chemical group 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000006872 improvement Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000007538 neurilemmoma Diseases 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 abstract 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 208000001608 teratocarcinoma Diseases 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40799902P | 2002-09-04 | 2002-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041136A1 true AR041136A1 (es) | 2005-05-04 |
Family
ID=31978544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103191A AR041136A1 (es) | 2002-09-04 | 2003-09-03 | Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas |
Country Status (19)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| KR20050057139A (ko) * | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| JP4564485B2 (ja) * | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| GB0305559D0 (en) * | 2003-03-11 | 2003-04-16 | Teijin Ltd | Compounds |
| BRPI0414238A (pt) * | 2003-09-09 | 2006-10-31 | Ono Pharmaceutical Co | antagonistas de crf e compostos heterobicìclicos |
| AR049769A1 (es) * | 2004-01-22 | 2006-09-06 | Novartis Ag | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| JP5334414B2 (ja) | 2004-09-06 | 2013-11-06 | バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のピラゾロピリミジン |
| FR2876583B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| EP1922321A1 (en) * | 2005-08-09 | 2008-05-21 | Eirx Therapeutics Ltd | Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them |
| CA2621983A1 (en) | 2005-09-09 | 2007-03-22 | Schering Corporation | Azafused cyclin dependent kinase inhibitors |
| CN101394853A (zh) * | 2006-03-08 | 2009-03-25 | 诺瓦提斯公司 | 吡唑并[1,5-a]嘧啶-7-基胺衍生物在神经性障碍的治疗中的用途 |
| WO2007118844A1 (de) * | 2006-04-13 | 2007-10-25 | Basf Se | Substituierte pyrazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel |
| US8507673B2 (en) * | 2008-12-11 | 2013-08-13 | Emory University | Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds |
| WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| WO2011028638A1 (en) | 2009-09-04 | 2011-03-10 | Schering Corporation | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| PH12012501643A1 (en) * | 2010-02-26 | 2017-07-19 | Mitsubishi Tanabe Pharma Corp | Pyrazolopyrimidine compounds and their use as pde 10 inhibitors |
| WO2012149157A2 (en) | 2011-04-26 | 2012-11-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2014066743A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2014066795A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| RU2015143517A (ru) * | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| JP2017501145A (ja) | 2013-12-23 | 2017-01-12 | ノージン ビーブイ | Ｃｃｒ９調節因子として有用な化合物 |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| CN106699785A (zh) * | 2015-07-13 | 2017-05-24 | 南开大学 | 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物 |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| CN108700594B (zh) | 2015-11-18 | 2021-06-29 | 建新公司 | 多囊性肾病的生物标志物及其用途 |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| EP4717312A1 (en) * | 2024-09-27 | 2026-04-01 | Perha Pharmaceuticals | Pyrazolo[1,5-a]pyrimidine derivatives useful as a medicament |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4116288Y1 (cg-RX-API-DMAC10.html) | 1964-11-07 | 1966-07-28 | ||
| JPS6157587A (ja) * | 1984-08-29 | 1986-03-24 | Shionogi & Co Ltd | 縮合複素環誘導体および抗潰瘍剤 |
| DE69130683T2 (de) * | 1991-04-22 | 1999-05-06 | Otsuka Pharmaceutical Factory, Inc., Naruto, Tokushima | PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL |
| JP3275389B2 (ja) * | 1991-09-06 | 2002-04-15 | 三菱ウェルファーマ株式会社 | ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物 |
| US5571813A (en) * | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
| EP0628559B1 (en) | 1993-06-10 | 2002-04-03 | Beiersdorf-Lilly GmbH | Pyrimidine compounds and their use as pharmaceuticals |
| GB9325074D0 (en) | 1993-12-07 | 1994-02-02 | Zeneca Ltd | Bicyclic heterocycles |
| EP0714898B1 (en) * | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
| US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| JPH10101672A (ja) * | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
| JPH10101671A (ja) * | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
| US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6413974B1 (en) * | 1998-02-26 | 2002-07-02 | Aventis Pharmaceuticals Inc. | 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
| JPH11292879A (ja) * | 1998-04-08 | 1999-10-26 | Otsuka Pharmaceut Factory Inc | カルボキサミド誘導体 |
| FR2805160B1 (fr) | 2000-02-23 | 2002-04-05 | Oreal | Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture |
| JP2002053466A (ja) * | 2000-08-08 | 2002-02-19 | Otsuka Pharmaceut Factory Inc | アポトーシス調整剤 |
| US7067520B2 (en) | 2000-11-17 | 2006-06-27 | Ishihara Sangyo Kaisha, Ltd. | Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts |
| FR2817469B1 (fr) | 2000-12-04 | 2003-04-18 | Oreal | Composition de coloration, procede d'obtention et utilisation pour la coloration de fibres keratiniques |
| JP2004516297A (ja) | 2000-12-20 | 2004-06-03 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） | サイクリン依存性キナーゼ（ｃｄｋ）及びグリコーゲンシンターゼキナーゼ−３（ｇｓｋ−３）の阻害剤 |
| CA2483306A1 (en) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
| DE10223917A1 (de) | 2002-05-29 | 2003-12-11 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| KR20050057139A (ko) * | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
-
2003
- 2003-09-03 KR KR1020057003687A patent/KR20050057139A/ko not_active Ceased
- 2003-09-03 AU AU2003268385A patent/AU2003268385B2/en not_active Ceased
- 2003-09-03 NZ NZ539164A patent/NZ539164A/en not_active IP Right Cessation
- 2003-09-03 AR ARP030103191A patent/AR041136A1/es unknown
- 2003-09-03 DE DE60317077T patent/DE60317077T2/de not_active Expired - Lifetime
- 2003-09-03 EP EP03749347A patent/EP1534710B1/en not_active Expired - Lifetime
- 2003-09-03 ES ES03749347T patent/ES2291665T3/es not_active Expired - Lifetime
- 2003-09-03 AT AT03749347T patent/ATE376548T1/de not_active IP Right Cessation
- 2003-09-03 WO PCT/US2003/027502 patent/WO2004022560A1/en not_active Ceased
- 2003-09-03 JP JP2004534459A patent/JP4700344B2/ja not_active Expired - Fee Related
- 2003-09-03 TW TW092124328A patent/TWI335919B/zh not_active IP Right Cessation
- 2003-09-03 US US10/653,868 patent/US7074924B2/en not_active Expired - Fee Related
- 2003-09-03 CN CNA038247798A patent/CN1701074A/zh active Pending
- 2003-09-03 MY MYPI20071386A patent/MY141978A/en unknown
- 2003-09-03 CA CA2497450A patent/CA2497450C/en not_active Expired - Fee Related
- 2003-09-03 MX MXPA05002570A patent/MXPA05002570A/es active IP Right Grant
- 2003-09-03 MY MYPI20033322A patent/MY137888A/en unknown
- 2003-09-04 PE PE2003000899A patent/PE20040999A1/es not_active Application Discontinuation
-
2005
- 2005-02-24 IL IL167088A patent/IL167088A/en not_active IP Right Cessation
- 2005-03-03 ZA ZA200501852A patent/ZA200501852B/en unknown
-
2006
- 2006-03-31 US US11/395,824 patent/US7309705B2/en not_active Expired - Fee Related
-
2007
- 2007-07-17 US US11/779,050 patent/US7511049B2/en not_active Expired - Fee Related
-
2010
- 2010-05-14 JP JP2010112695A patent/JP2010168406A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE60317077T2 (de) | 2008-07-24 |
| US7511049B2 (en) | 2009-03-31 |
| US20040116442A1 (en) | 2004-06-17 |
| JP2006502161A (ja) | 2006-01-19 |
| ATE376548T1 (de) | 2007-11-15 |
| AU2003268385B2 (en) | 2006-12-21 |
| ES2291665T3 (es) | 2008-03-01 |
| WO2004022560A9 (en) | 2005-07-07 |
| IL167088A (en) | 2010-12-30 |
| JP4700344B2 (ja) | 2011-06-15 |
| NZ539164A (en) | 2006-04-28 |
| MY141978A (en) | 2010-08-16 |
| US20070275983A1 (en) | 2007-11-29 |
| TWI335919B (en) | 2011-01-11 |
| KR20050057139A (ko) | 2005-06-16 |
| HK1071569A1 (en) | 2005-07-22 |
| CA2497450A1 (en) | 2004-03-18 |
| US20060173016A1 (en) | 2006-08-03 |
| TW200420564A (en) | 2004-10-16 |
| EP1534710B1 (en) | 2007-10-24 |
| WO2004022560A1 (en) | 2004-03-18 |
| US7074924B2 (en) | 2006-07-11 |
| AU2003268385A1 (en) | 2004-03-29 |
| MXPA05002570A (es) | 2005-09-08 |
| DE60317077D1 (de) | 2007-12-06 |
| CA2497450C (en) | 2011-05-31 |
| MY137888A (en) | 2009-03-31 |
| ZA200501852B (en) | 2005-09-08 |
| US7309705B2 (en) | 2007-12-18 |
| PE20040999A1 (es) | 2004-12-28 |
| EP1534710A1 (en) | 2005-06-01 |
| JP2010168406A (ja) | 2010-08-05 |
| CN1701074A (zh) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041135A1 (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas | |
| AR041133A1 (es) | Pirazolopirimidinas como inhibidores de la quinasa dependientes de la ciclina | |
| AR041134A1 (es) | Pirazolopirimidinas como inhibidores de la quinasa dependiente de ciclina | |
| AR056206A1 (es) | Pirazolpirimidinas como inhibidores de protein quinasas | |
| JP2021514400A5 (cg-RX-API-DMAC10.html) | ||
| AR041291A1 (es) | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina | |
| JP2006507254A5 (cg-RX-API-DMAC10.html) | ||
| BRPI0312547B8 (pt) | uso de derivados de imidazo [4,5-c]piridina como inibidores virais | |
| UY26914A1 (es) | Derivados nucleósidos | |
| AR061118A1 (es) | Derivados de pirimidina, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de cdk2. | |
| PE20091371A1 (es) | Inhibidores de hsp90 | |
| CN110167939A (zh) | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 | |
| UY28084A1 (es) | Derivados antivirales de nucleosidos | |
| JP2006502161A5 (cg-RX-API-DMAC10.html) | ||
| EP3218378A1 (en) | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | |
| EA201290993A1 (ru) | Нуклеозидфосфорамидаты | |
| DK1719773T3 (da) | Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor | |
| PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
| ECSP055964A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| AR041346A1 (es) | Derivados de imidazol[1,2-a]pirazinas como inhibidores de quinasas dependientes de ciclinas | |
| PE20040999A1 (es) | Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas | |
| TW200621761A (en) | Heterocyclic antiviral compounds | |
| DE68925278D1 (de) | Hemmung von htlv-iii durch exogene oligonukleotide | |
| TW200609204A (en) | Sulfonamide derivatives, preparation thereof and therapeutic application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |